Carina Kern
CEO
LinkGevity
LinkGevity applies AI and proprietary Blueprint Theory to map the biological triggers of aging, focusing on necrosis as a key driver of health decline. The company develops first‑in‑class necrosis inhibitors (Anti‑Necrotics™) for therapeutic areas such as kidney disease and for non‑clinical uses like tissue engineering. It monetizes its pipeline through drug development, licensing agreements, and partnership collaborations with pharmaceutical and biotech firms.
- Biotechnology
Updated 23 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Necrosis, the uncontrolled death of cells and tissues, is a key biological trigger of aging and a significant obstacle in fields like tissue engineering, organ preservation, and chronic disease treatment. This process is mechanistically linked to accelerated aging and hinders efforts to extend healthspan.
Solution
LinkGevity is developing first-in-class Anti-Necrotics™ to inhibit necrosis and its downstream effects. By targeting this fundamental mechanism of cellular demise, LinkGevity aims to increase healthspan and improve outcomes in various applications. Their approach involves building proprietary Blueprint Maps, which are used to identify and intervene in the biological triggers of aging. The company is actively pursuing partnerships and licensing opportunities to maximize the impact of their Anti-Necrotics™ pipeline.
Target Audience
The primary target audience includes researchers and companies in tissue engineering, regenerative medicine, and pharmaceutical development focused on aging-related diseases and acute kidney injury.
Features
- Anti-Necrotics™ are first-in-class necrosis inhibitors.
- Pipeline covers both clinical (Acute Kidney Injury) and non-clinical (e.g., tissue engineering) applications.
- Proprietary Blueprint Maps are used to identify and target biological triggers of aging.
- LINK Non-Clinical program is ready to license as a platform technology.
- LINK Clinical program for Acute Kidney Injury is expedited to Phase 2.